Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The New Economy and its Winners -- Ignore unavailable to you. Want to Upgrade?

To: Tom Kearney who wrote (26896)	1/13/2006 6:35:43 PM
From: Bill Harmond	Read Replies (1) \| Respond to of 57684

12:48 STXS Stereotaxis -- Momentum Profile (11.13 +0.86) -Update- A stock making a strong move this week is Stereotaxis, The co makes an advanced cardiology instrument control system designed to allow physicians to navigate catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The system uses computer-controlled, externally applied magnetic fields that govern the motion of the working tip. The co believes it revolutionizes the treatment of coronary artery disease and arrhythmias and has the potential to become the "standard of care" for a broad range of complex cardiology procedures. Traditionally, cardiac procedures have been performed via open chest heart bypass surgery. This procedure is very invasive, requiring cutting open the rib cage and spreading it apart. The co believes its system is the only technology to be commercialized that allows remote, computerized control. The co has no direct competitors in this field. US approval has been slower than expected leading to flat yr/yr sales for the 9 mos ended Sep 30 at $12.9 mln. However, that appears to be changing. Last month, the FDA approved a Johnson & Johnson catheter system that integrates Stereotaxis' magnetic navigation system. Yesterday, the co announced a significant milestone with three leading electrophysiology sites becoming the first US centers to successfully treat cardiac arrhythmias.... Although this somewhat-recent IPO debuted back in Aug 2004, lately traders have been seeking underperforming IPOs and pushing them higher. STXS looks interesting as it is close to testing its post-IPO high of $12.67. Mkt cap $314 mn, float 18.5 mn, avg vol 155K.

To: Tom Kearney who wrote (26896)	1/15/2006 6:19:45 PM
From: Harvey Allen	Respond to of 57684

A friend and good customer emailed me a copy of a news article that stated “AMD Shares Drop After Dell Rumor Quelled”. This friend is heavily invested into many successful companies, and he asked for my opinion on this news. I had to laugh when I read this article, because you figure an analyst would perform real research before making sweeping statements. Personally, I only trust investment firms who deal with companies like Gerson Lehman as they tend to pay top dollar for informed research. I’m not professing to be a stock analyst, but I do understand the technology and the roadmaps better than any analyst that I have ever had the pleasure of speaking with. I figured I’d dissect this news line by line. voodoopc.blogspot.com